Cat. No. | Product name | CAS No. |
DC7672 |
SAR125844
Featured
SAR125844 is inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. |
1116743-46-4 |
DC7276 |
Saracatinib (AZD0530)
Featured
Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). |
379231-04-6 |
DC12276 |
Saridegib (IPI-926; Patidegib)
Featured
Saridegib is a potent and specific inhibitor of Smoothened (Smo), a key signaling transmembrane protein in the Hedgehog (Hh) pathway. |
1037210-93-7 |
DC5137 |
SB 743921
Featured
SB743921 is a kinesin spindle protein (KSP) inhibitor with Ki of 0.1 nM, almost no affinity to MKLP1, Kin2, Kif1A, Kif15, KHC, Kif4 and CENP-E. |
940929-33-9 |
DC5024 |
MK-8776 (SCH 900776)
Featured
SCH 900776 is a selective Chk1 inhibitor with IC50 of 3 nM. It shows 50-fold selectivity against Chk2. Phase 2. |
891494-63-6 |
DC7283 |
SCH-772984
Featured
SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 of 4 nM and 1 nM, respectively. |
942183-80-4 |
DC7290 |
Semaxanib (SU5416)
Featured
Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR. |
204005-46-9 |
DC11812 |
SF-1126
SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins. |
936487-67-1 |
DC6313 |
Guadecitabine(SGI-110)
Featured
SGI-110 (S-110) is a stable and potent inhibitor for DNA methylation, inhibits DNMT1 when SGI-110 is activated by phosphorylation and incorporated into DNA. |
929901-49-5 |
DC7160 |
SGI-1776
Featured
SGI-1776 is a novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM; 50- and 10-fold selective versus Pim2 and Pim3, also potent to Flt3 and haspin. |
1025065-69-3 |
DC7294 |
SGX-523
Featured
SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. |
1022150-57-7 |
DC10632 |
Sitravatinib (MGCD516)
Featured
Sitravatinib (MGCD516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl. |
1123837-84-2 |
DC8049 |
SNG-1153
Featured
SNG-1153 is a synthetic modulator of ER-α36 |
1446712-19-1 |
DC7297 |
SNS-032(BMS-387032)
Featured
SNS-032(BMS-387032) is a potent inhibitor of cyclin-dependent kinases (cdks) 9, 2 and 7 (IC50 values are 4, 38 and 62 nM respectively). |
345627-80-7 |
DC2098 |
Sorafenib (BAY-43-9006)
Featured
Sorafenib Tosylate (Bay 43-9006, Nexavar) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. |
475207-59-1 |
DC8791 |
Sorafenib free base (BAY-43-9006)
Featured
Sorafenib(BAY 43-9006) is a potent inhibitor of Raf-1 with IC50 values of 6 nM, 22 nM and 90 nM for Raf-1, B-Raf, and VEGFR2 respectively, BAY 43-9006 suppresses both wild-type and V599E mutant BRAF activity in vitro. |
284461-73-0 |
DC7506 |
Sotrastaurin
Featured
Sotrastaurin(AEB-071) is a potent and selective pan-PKC inhibitor, mostly for PKCθ with Ki of 0.22 nM; inactive to PKCζ. |
425637-18-9 |
DC4131 |
SR48692
Featured
SR 48692 is a neurotensin antagonist; selective for NTS1 over NTS2 (apparent affinity, Ke, is 36 nM for NTS1). Competitively inhibits binding of [125I]-neurotensin to HT29 and N1E115 cell membranes (IC50 values are 15.3 and 20.4 nM respectively). |
146362-70-1 |
DC10456 |
STF-62247
Featured
STF-62247 is a small molecule agonist that induces autophagy and selectively causes lethality in renal cell carcinoma (RCC) cells that have lost the von Hippel-Lindau (VHL) tumor suppressor activity (IC50 = 625 nM). |
315702-99-9 |
DC7302 |
SU14813
Featured
SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), Kit, and fms-like tyrosine kinase 3 (FLT-3). |
627908-92-3 |
DC5079 |
Orantinib (TSU-68)
Featured
SU6668 has greatest potency against PDGFR autophosphorylation with Ki of 8 nM, but also strongly inhibits Flk-1 and FGFR1 trans-phosphorylation, little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2; does not inhibit EGFR. |
252916-29-3 |
DC6906 |
Aprepitant (MK-0869, L-754030)
Featured
Substance P antagonists (SPA). |
170729-80-3 |